- Home
- CLDX vs TVTX Comparison
CLDX vs TVTX Comparison
Compare CLDX & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDX
- TVTX
- Stock Information
- Founded
- CLDX N/A
- TVTX 2008
- Country
- CLDX United States
- TVTX United States
- Employees
- CLDX N/A
- TVTX N/A
- Industry
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- CLDX Health Care
- TVTX Health Care
- Exchange
- CLDX Nasdaq
- TVTX Nasdaq
- Market Cap
- CLDX 1.4B
- TVTX 1.5B
- IPO Year
- CLDX 2008
- TVTX N/A
- Fundamental
- Price
- CLDX $22.08
- TVTX $17.50
- Analyst Decision
- CLDX Strong Buy
- TVTX Strong Buy
- Analyst Count
- CLDX 9
- TVTX 16
- Target Price
- CLDX $46.13
- TVTX $34.53
- AVG Volume (30 Days)
- CLDX 1.5M
- TVTX 1.7M
- Earning Date
- CLDX 08-07-2025
- TVTX 08-06-2025
- Dividend Yield
- CLDX N/A
- TVTX N/A
- EPS Growth
- CLDX N/A
- TVTX N/A
- EPS
- CLDX N/A
- TVTX N/A
- Revenue
- CLDX $5,790,000.00
- TVTX $333,865,000.00
- Revenue This Year
- CLDX N/A
- TVTX $83.26
- Revenue Next Year
- CLDX N/A
- TVTX $43.19
- P/E Ratio
- CLDX N/A
- TVTX N/A
- Revenue Growth
- CLDX N/A
- TVTX 87.94
- 52 Week Low
- CLDX $14.40
- TVTX $8.98
- 52 Week High
- CLDX $47.00
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- CLDX 47.99
- TVTX 53.75
- Support Level
- CLDX $21.34
- TVTX $17.05
- Resistance Level
- CLDX $23.27
- TVTX $19.57
- Average True Range (ATR)
- CLDX 1.54
- TVTX 0.79
- MACD
- CLDX -0.15
- TVTX -0.10
- Stochastic Oscillator
- CLDX 33.75
- TVTX 17.89
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.